Boston Scientific enrolls stent trials patients

Boston Scientific Corp., the Natick medical devices giant, has begun enrolling patients in its Platinum clinical trial to test the company’s Promus Element Everolimus Coronary Stent. With two patients enrolled last week in the U.S. and Japan, the trial is expected to test about 1,728 people at 160 global facilities, and it should be fully enrolled by October.